Context Therapeutics opened lower at $0.21, compared with its previous close of $0.22. In the last trading session, the stock traded between $0.20 and $0.21. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Context Therapeutics is now worth
$ 3.79
Resulting in a loss of
$ 96.21 (96.21%)
Note: Past profits do not guarantee future returns.
Rating from 1 Analysts
Today's Change
$-0.02 (-8.38%)
Day High
$0.21
Day Low
$0.20
Day Open
$0.21
Prev Close
$0.22
Volume
4,82,752
1W Return
-3.41%
1M Return
-34.44%
3M Return
-57.69%
6M Return
-91.72%
1Y Return
-83.36%
Market Cap ($ Mn)
18
PE Ratio
-
PB Ratio
0.92
PEG Ratio
-
ROE
-44.88%
ROCE
-49.05%
EPS (TTM)
$-0.16
1 Week
-3.41%
1 Month
-34.44%
3 Months
-57.69%
6 Months
-91.72%
9 Months
-91.89%
Context Therapeutics Q3FY27 Results: Loss narrows to $(0.08), beats estimate
Net loss narrowed to $7.6 million in Q3FY27 from $9.7 million in Q3FY26. EPS loss of $(0.08) beat analyst consensus of $(0.11). CTIM-76 showed 22% ORR and 5.6-month median PFS in PROC patients. Cash reserves of $34.4 million expected to fund operations to early Q4 2027. R&D expenses fell 34.5% YoY driven by lower CT-202 costs.
2 days agoContext Therapeutics Q2 loss widens to $14.6M; shares plunge 30%
Context Therapeutics reported a Q2 2026 net loss of $14.6 million, widening from $8.8 million in the prior year, driven by increased R&D and G&A expenses. Shares plunged 30.45% after hours to $0.48. The company discontinued CT-95 development to focus on CTIM-76 and CT-202, expecting initial data in Q2 2027.
3mo agoContext Therapeutics gets time through Jan 25 to fix Nasdaq compliance
Context Therapeutics faces a Nasdaq noncompliance notice with a cure period ending January 25, 2027. The company must address the listing deficiency to avoid delisting proceedings. Failure to comply could result in significant negative consequences for shareholders, including reduced liquidity and market visibility. The specific nature of the noncompliance is not disclosed in the current filing.
3mo agoContext Therapeutics grants inducement stock options to new employee
Context Therapeutics Inc. granted 146,000 stock options to a new employee at $0.70 per share as an employment inducement under Nasdaq Rule 5635(c)(4). The options, granted on July 7, 2026, have a 10-year term and vest over four years, with 25% vesting on the first anniversary and the remainder in monthly installments.
4mo agoContext Therapeutics added to Russell 2000 and Russell 3000 Indexes
Context Therapeutics Inc. was added to the small-cap Russell 2000 and the broad-market Russell 3000 Indexes effective June 26, 2026, enhancing its visibility among investors.
4mo agoMaxim Group maintains Buy on Context Therapeutics, cuts target to $4
Maxim Group analyst Jason McCarthy maintained a Buy rating on Context Therapeutics but lowered the price target from $8 to $4. The revised target reflects a reassessment of the NASDAQ-listed company's valuation.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Context Therapeutics is now worth
$ 3.79
Resulting in a loss of
$ 96.21 (96.21%)
Note: Past profits do not guarantee future returns.
